Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...

The current PI3K 3C inhibitors in use in advanced breast cancer are alpelisib and inavolisib. Capivasertib is an AKT inhibitor, which is also used in PI3K 3C mutated breast cancer. So these are ...

Now a study by O'Brien and coauthors has unraveled the role of PI3K/AKT signaling. “We observed that the majority of our trastuzumab resistant cell lines remain sensitive to lapatinib ...